Drug therapy for heart failure with reduced ejection fraction: what is the 'right' dose?

Abstract

New guidelines have emphasized the primacy of starting the four key life-saving therapies for patients with heart failure and reduced ejection fraction as quickly as possible, with titration to 'target dose' of these, as secondary consideration. In this article, we examine the reasons for this change in emphasis and revisit the evidence regarding the dosing of pharmacological therapy in heart failure. We demonstrate the early benefits obtained with even low doses of most of the foundational therapies for heart failure and reduced ejection fraction. We also clarify that the 'target dose' of those therapies requiring titration was a goal based on tolerability and often not reached in trials, i.e. the proven benefits of our foundational therapies were demonstrated with an average dose that was less than target and many patients in these trials were treated with sub-target doses.

• Authors: Toru Kondo, Pardeep S Jhund, John J V McMurray
• Journal: European journal of heart failure (Eur J Heart Fail) Vol. 24 Issue 3 Pg. 421-430 (03 2022) ISSN: 1879-0844 [Electronic] England
• PMID: 35119172 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Topics

• Heart Failure (drug therapy)
• Humans
• Stroke Volume
• Ventricular Dysfunction, Left